ESTRO 2024 - Abstract Book

S1917

Clinical - Mixed sites, palliation

ESTRO 2024

Conclusion:

Despite the small population, the cancers heterogeneity, and the short follow up time, to our knowledge this is one of the fist studies reporting exclusive LRT efficacy. Our data shows that exclusive LRT, administered in 5 consecutive days, can safely achieve dramatic responses in patients affected by large neoplastic lesions in a relative short time.

Keywords: Lattice Radiation Therapy, Large Cancer

References:

[1] Duriseti S, Kavanaugh J, Goddu S, Price A, Knutson N, Reynoso F, Michalski J, Mutic S, Robinson C, Spraker MB. Spatially fractionated stereotactic body radiation therapy (Lattice) for large tumors. Adv Radiat Oncol. 2021 Jan 8;6(3):100639. doi: 10.1016/j.adro.2020.100639. PMID: 34195486; PMCID: PMC8233471. [2] Duriseti S, Kavanaugh JA, Szymanski J, Huang Y, Basarabescu F, Chaudhuri A, Henke L, Samson P, Lin A, Robinson C, Spraker MB. LITE SABR M1: A phase I trial of Lattice stereotactic body radiotherapy for large tumors. Radiother Oncol. 2022 Feb;167:317-322. doi: 10.1016/j.radonc.2021.11.023. Epub 2021 Dec 4. PMID: 34875286. [3] Iori F, Cappelli A, D'Angelo E, Cozzi S, Ghersi SF, De Felice F, Ciammella P, Bruni A, Iotti C. Lattice Radiation Therapy in clinical practice: A systematic review. Clin Transl Radiat Oncol. 2022 Dec 20;39:100569. doi: 10.1016/j.ctro.2022.100569. PMID: 36590825; PMCID: PMC9800252.

1437

Digital Poster

Initial Experience of MR-Guided Stereotactic Body Radiation Therapy for Cardiac Targets

Alexander Rosenfeld 1 , Jeremy De Leon 2 , Vikneswary Batumalai 2,3 , Tommy Liang 1 , Amrinder Chhabra 1 , Katrina Biggerstaff 1 , Nicole Hug 1 , Eugene Leong 1 , Kasri Rahim 1 , David Crawford 2 , Michael Jameson 2,3 , Hendrick Tan 1,4 1 GenesisCare, Murdoch, Perth, Australia. 2 GenesisCare, St Vincent's Hospital, Sydney, Australia. 3 School of Clinical Medicine, Faculty of Medicine and Health, UNSW, Sydney, Australia. 4 Department of Radiation Oncology, Fiona Stanley Hospital, Perth, Australia

Purpose/Objective:

Primary cardiac malignancies are extremely rare, with a reported incidence of < 0.3% 1 , whereas cardiac metastases are more common, with an estimated incidence of 8.4% 2 . Cardiac targets pose a significant clinical challenge due to physiological movement, difficulty with soft tissue delineation and lack of image guidance capacity. The emergence of MR-guided radiotherapy (MRgRT) has permitted real-time, dynamic guidance with superior soft tissue delineation